Stock Symbol:   

Stoxline Mobile
Home  |  Stock Charts  |  Showcases  |  Stock Ranks  |  Options  |  ETFs  |  Educations  |  Forex Crypto

Alexion Pharm Inc (ALXN)

153.84   -0.65 (-0.42%) 02-25 11:44
Open: 155.23 Pre. Close: 154.49
High: 155.48 Low: 153.84
Volume: 448,439 Market Cap: 33,821M
Alexion Pharmaceuticals, Inc. develops and commercializes various therapeutic products. The company offers ULTOMIRIS (ALXN1210/ravulizumab-cwvz), a C5 inhibitor for the treatment of paroxysmal nocturnal hemoglobinuria (PNH) and atypical hemolytic uremic syndrome (aHUS); and SOLIRIS (eculizumab), a monoclonal antibody for the treatment of PNH, aHUS, generalized myasthenia gravis (gMG), and neuromyelitis optica spectrum disorder (NMOSD). It also provides Strensiq (asfotase alfa), a targeted enzyme replacement therapy for patients with hypophosphatasia; and Kanuma (sebelipase alfa) for the treatment of patients with lysosomal acid lipase deficiency. In addition, the company is developing ALXN1210 (Intravenous) that is in Phase III clinical trials for the treatment of gMG and NMOSD; ALXN1210 (Subcutaneous), which is in Phase III clinical trials for PNH and aHUS; ALXN1810 (Subcutaneous) that is in Phase I clinical trial for renal diseases; and ALXN1720 (Subcutaneous), which is in Phase I clinical trial for the treatment of disease states involving dysregulated terminal complement activity. Further, it is developing ALXN1840 (WTX101) that is in Phase III clinical trials for the treatment of Wilson disease; and ALXN1830 and ABY-039, which are in Phase I clinical trials for neonatal Fc receptor. The company serves distributors, pharmacies, hospitals, hospital buying groups, and other healthcare providers in the United States and internationally. Alexion Pharmaceuticals, Inc. has collaboration and license agreement with Halozyme Therapeutics, Inc.; collaborations with Caelum Biosciences, Inc., Dicerna Pharmaceuticals, Inc. and Zealand Pharma A/S; strategic agreement with Caelum Biosciences, Inc.; agreement with Stealth BioTherapeutics Corp.; and a partnership with Affibody AB. The company was founded in 1992 and is headquartered in Boston, Massachusetts.

Stock Price Prediction

Update at 5:00pm EST
If tomorrow: Open lower Open higher
High: 155.163 - 156.1 156.1 - 156.998
Low: 150.83 - 151.94 151.94 - 153.003
Close: 152.791 - 154.424 154.424 - 155.989

Technical analysis

as of: 2021-02-25 11:07:47 AM
Stoxline posted a SELL today, same as yesterday. Downward movement continues.
Target: Six months: 185.48     One year: 189.92
Support: Support1: 152.65    Support2: 127.00
Resistance: Resistance1: 158.80    Resistance2: 162.60
Pivot: 155.36
Moving Average: MA(5): 154.44     MA(20): 155.31
MA(100): 138.94     MA(250): 117.98
MACD: MACD(12,26): 0.25     Signal(9): 0.75
Stochastic oscillator: %K(14,3): 22.22     %D(3): 22.12
RSI: RSI(14): 48.80
52-week: High: 162.60  Low: 72.67  Change(%): 64.3
Average Vol(K): 3-Month: 307651  10-Days: 212994

Price, moving averages and Bollinger Bands

Price and moving averages has closed below its Short term moving average. Short term moving average is currently below mid-term; AND above long term moving averages. From the relationship between price and moving averages; we can see that: This stock is BEARISH in short-term; and NEUTRAL in mid-long term.
ALXN has closed above bottom band by 34.5%. Bollinger Bands are 67.5% narrower than normal. The narrow width of the bands suggests low volatility as compared to ALXN's normal range. The bands have been in this narrow range for 35 bars. This is a sign that the market may be about to initiate a new trend.

Headline News

Mon, 22 Feb 2021
How Many Alexion Pharmaceuticals, Inc. (NASDAQ:ALXN) Shares Do Institutions Own? - Yahoo Finance

Mon, 22 Feb 2021
Arcturus Therapeutics Acquires Exclusive License to mRNA Manufacturing Technology from Alexion Pharmaceuticals - Business Wire

Tue, 16 Feb 2021
Valuation: Alexion Pharmaceuticals (ALXN) Stock Looks Attractive. $215.0 Trefis Price (36% Upside). [2/16/2021] - Trefis

Fri, 12 Feb 2021
Alexion Pharmaceuticals, Inc. (NASDAQ:ALXN) Expected to Post Quarterly Sales of $1.57 Billion - MarketBeat

Thu, 11 Feb 2021
ALXN vs. BMRN: Which Stock Is the Better Value Option? - Yahoo Finance

Thu, 04 Feb 2021
Alexion Pharmaceuticals EPS beats by $0.40, beats on revenue - Seeking Alpha

Financial Analysis

Growth measures the growth of both a company's revenue and net income. it tells investors how fast a company is growing.
Profitability measures a company’s ability to generate earnings as compared to its expenses and other relevant costs.
Solvency measures a company's ability to meet its long-term debts. Acceptable solvency ratios will vary from industry to industry.
Efficiency measures the strength of a company's return on invested capital. It can identify business that are better managed or not.
Price to Book Value: Outperform Discounted cash flow: Outperform
Return on Assets: Neutral Price to Earnings: Outperform
Return on Equity: Neutral Debt to Equity: Outperform
Free Technical Analysis Charts

Stock Basics & Statistics

Exchange:  NASDAQ
Sector:  Healthcare
Industry:  Biotechnology
Shares Out. (M) 219
Shares Float (M) 218
% Held by Insiders 0.28
% Held by Institutions 93.36
Shares Short (K) 3,870
Shares Short P. Month (K) 3,530

Stock Financials

EPS 4.310
EPS Est This Year 5.620
EPS Est Next Year 7.130
Book Value (p.s.) 50.570
Profit Margin 16.32
Operating Margin 47.42
Return on Assets (ttm) 10.7
Return on Equity (ttm) 8.9
Qtrly Rev. Growth 25.8
Gross Profit (p.s.) 21.031
Sales Per Share 26.792
EBITDA (p.s.) 14.173
Qtrly Earnings Growth 23.60
Operating Cash Flow (M) 2,680
Levered Free Cash Flow (M) 1,790

Stock Valuations

PE Ratio 35.84
PEG Ratio
Price to Book value 3.05
Price to Sales 5.76
Price to Cash Flow 12.61

Stock Dividends

Forward Dividend
Dividend Yield
Dividend Pay Date Invalid DateTime.
Ex-Dividend Date Invalid DateTime.
7 Binary Options
Your Ad Here
Stock Chart
Stoxline Lite
Stoxline Pro
Option Calculator
(c) 2006-2020 | Contact us           
Data and information is provided for informational purposes only, and is not intended for trading purposes. Neither nor its data provider shall be liable for any errors or delays in the content, or for any actions taken in reliance thereon. By accessing the web site, a user agrees not to redistribute the information found therein.